Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

EACTS Annual Meeting 2022

More than 3.500 Heart and Thorax Physicians from all over the world attended the 36th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in Milan from October 5 to 8, 2022. Resuscitec GmbH presented itself for the first time with its own booth in the Milano Convention Center (MiCo) and introduced the CARL Therapy as well as the CARL System to many interested parties from Europe, Asia and America.

“Our second international appearance with CARL was very successful. The cooperation with our South-European distribution partners Gada Italia and Palex Medical (Spain & Portugal) worked very well. In addition, we were able to establish many new contacts, which will further accelerate the ongoing market entry in Europe,” says Dr. Patrick Rauh, Head of Sales of Resuscitec GmbH.

150 participants at the satellite symposium CARL Therapy

The satellite symposium on „CARL. Controlled Automated Reperfusion of the whoLe body – A new concept treating patients with cardiac arrest” on Thursday, October 6, was very well attended by 150 participants. Dr. Jan-Steffen Pooth of the Medical Center – University of Freiburg presented the results of the current resuscitation practice and explained the scientific background for the further development towards CARL Therapy. Afterwards Dr. Hug Aubin from the University Hospital Düsseldorf lectured on the implementation of the CARL System in daily clinical practice and presented the first clinical results of the patients treated so far in his hospital.

Prof. Christoph Benk explained the product technical function of the individual components of the CARL System, their practical use from a perfusionist’s point of view and the integration of the system into the Freiburg process landscape for internal and prehospital resuscitation. He and Prof. Georg Trummer, who presented the multicenter clinical results to date, come from the Medical Center – University of Freiburg.

< Back